The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Risk of Stevens–Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics
Abstract
BACKGROUND: Estimates of risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) associated with some antiepileptic drugs (AEDs) have used denominators based on the number of prescriptions or daily doses. Because the risk of SJS is highest in new users of drugs, the use of denominators reflective of all users can lead to low estimates of risk associated with drugs. In this study, risk in new users is assessed. METHODS: Data on all hospitalized patients with SJS and TEN with use of carbamazepine (CBZ), lamotrigine (LTG), phenobarbital (PHB), phenytoin (PHT), or valproic acid (VPA) were obtained from the German Registry for Serious Cutaneous Reactions. For 1998-2001, the numbers of new users were estimated from number of dispensed prescriptions in Germany, the average prescribed doses, and the duration of use in the Mediplus database (IMS Health) Germany, and assumptions that relate new use to growth in national dispensings. To minimize the probability of underestimating risk in new users, conservative estimates of new use that were somewhat lower than predicted from national prescription data were used. RESULTS: More than 90% of SJS and TEN cases occurred in the first 63 days of AED use. Over the 4 years, increases in dispensing were 5% for CBZ, 65% for LTG, 6% for PHB, -16% for PHT, and 26% for VPA. Across a range of assumptions about frequency of incident use, the risk estimates vary between 1 and 10 per 10,000 new users for CBZ, LTG, PHT, and PHY and were consistently lower for VPA. CONCLUSION: Across a range of assumptions used, the risk of hospitalization for Stevens-Johnson syndrome or toxic epidermal necrolysis in new users is low for carbamazepine, lamotrigine, phenytoin, phenobarbital, and valproic acid. Because conservative incidence use fractions were used, it is likely that some risks were overestimated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rzany, B., Correia, O., Kelly, J. P., Naldi, L., Auquier, A., & Stern, R. (1999) · The Lancet · doi:10.1016/s0140-6736(98)05418-x · Cited by 348
Safety Review of Adult Clinical Trial Experience with Lamotrigine
Messenheimer, J., Mullens, E. L., Giorgi, L., & Young, F. (1998) · Drug Safety · doi:10.2165/00002018-199818040-00004 · Cited by 252
Self-citation
Cited by
Dols, A., Sienaert, P., van Gerven, H., Schouws, S., Stevens, A., Kupka, R., & Stek, M. L. (2013) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32836435e2 · Cited by 86
Metadata
- Authors
- Mockenhaupt, M., Messenheimer, J., Tennis, P., & Schlingmann, J.
- Venue
- Neurology
- Published
- 2005-04-12
- Volume
- 64
- Issue
- 7
- Pages
- 1134-1138
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2108686931
- Cited by
- 399
- References
- 2
- FWCI
- 12.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risk of Stevens–Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. https://app.cochat.ai/papers/10.1212/01.wnl.0000156354.20227.f0
- The paper
- Mockenhaupt, M., Messenheimer, J., Tennis, P., & Schlingmann, J. (2005). Risk of Stevens–Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology. https://doi.org/10.1212/01.wnl.0000156354.20227.f0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.